Business
Notice of H1 Results
Notice of H1 Results.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 2819F IXICO plc 16 May 2017 \n\n16 May 2017\n \nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nNotice of Interim Results\n \nIXICO, the brain health company, will announce its interim results for the six months ended 31 March 2017 on Monday 22 May 2017.\n \nFor further information please contact: \n\n\n\n\nIXICO plc \nSusan Lowther, Chief Financial Officer\n\n\n \nTel: +44 20 3763 7499\n \n\n\n\n\nShore Capital (Nomad and Broker)\nBidhi Bhoma / Edward Mansfield\n\n\nTel: +44 20 7408 4090\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting Limited (Investor Relations)\nSimon Conway/Mo Noonan\n\n\nTel: +44 20 3727 1000\n\n\n\n\n \nAbout IXICO\nOur mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global Pharmaceutical industry to select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis and Parkinson's and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant patient clinical data to enable sponsors to make rapid, better informed decisions. \n \nIXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes\n \nMore information is available on www.ixico.com\n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NOREAPSKFSXXEEF\n ","length":3698,"tagName":"div"}]